GlaxoSmithKline Pharmaceuticals Performance
- Today's Low
- ₹2,340
- Today's High
- ₹2,398
- 52 Week Low
- ₹2,218
- 52 Week High
- ₹3,516
- Open Price₹2,388
- Previous Close₹2,389
- Volume80,193
- 50 DMA₹2,417.91
- 100 DMA₹2,460.59
- 200 DMA₹2,535.08
GlaxoSmithKline Pharmaceuticals Chart
Investment Returns
- Over 1 Month -4.49%
- Over 3 Month -10.64%
- Over 6 Month -7.5%
- Over 1 Year -16.72%
Smart Investing Starts Here Start SIP with GlaxoSmithKline Pharmaceuticals for Steady Growth!
GlaxoSmithKline Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 37.9
- PEG Ratio
- 3.2
- Market Cap Cr
- 39,314
- P/B Ratio
- 19.6
- Average True Range
- 66.47
- EPS
- 60.26
- Dividend Yield
- 1.8
- MACD Signal
- -1.45
- RSI
- 38.37
- MFI
- 52.48
Latest Stock News Updates
GlaxoSmithKline Pharmaceuticals on Monday posted 29 per cent increase in consolidated profit after tax at Rs 296 crore for the third quarter ended December 31, 2025. The drugmaker reported a profit after tax of Rs 230 crore for the October-December period of last fiscal. Revenue from operations rose to Rs 1,041 crore from Rs 949 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals Ltd said in a regulatory filing. The company said its competitive performance comes against the backdrop of the broader macro environment and efforts to mitigate internal supply challenges. The implementation of the new Labour Codes did not have a material impact on the company, it added. Shares of the company on Monday settled 1.01 per cent up at Rs 2,511 apiece on BSE.
- Business Standard
- 3 months 1 week ago
Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q3FY26 results Revenue: Rs 1,04,126 lakh against Rs 94,942 lakh during Q3FY25, change 10%. PBT: Rs 39,993 lakh against Rs 30,810 lakh during Q3FY25, change 30%. PAT: Rs 29,562 lakh against Rs 22,988 lakh during Q3FY25, change 29%. EPS: Rs 16.54 for Q3FY26. Bhushan Akshikar, Managing Director, GSK India, said: “By moving immunotherapy from later lines to initial standard of care, the RUBY-1 trial has established a new paradigm in first-line treatment of endometrial cancer, and is now approved for this indication in India. The positive results on progression-free survival and overall survival in the population under trial will simplify decision-making for HCPs on treatment lines and benefit a wide range of endometrial cancer patients. Supported by comprehensive patient support and financing initiatives, the Company is leaving no stone unturned to ensure patients with cancer receive the highest standard of care.” Result PDF
- Trendlyne
- 3 months 1 week ago
GSK Pharma shares fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current financial year
- Business Standard
- 6 months 2 weeks ago
GlaxoSmithKline Pharmaceuticals Financials
GlaxoSmithKline Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 16
- Bullish Moving Average 0
- 20 Day
- ₹2,400.31
- 50 Day
- ₹2,417.91
- 100 Day
- ₹2,460.59
- 200 Day
- ₹2,535.08
Resistance and Support
- R3 2,427.13
- R2 2,403.17
- R1 2,361.93
- S1 2,296.73
- S2 2,272.77
- S3 2,231.53
GlaxoSmithKline Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
About GlaxoSmithKline Pharmaceuticals
- NSE Symbol
- GLAXO
- BSE Symbol
- 500660
- Managing Director
- Mr. B Akshikar
- ISIN
- INE159A01016
Similar Stocks to GlaxoSmithKline Pharmaceuticals
Popular Stocks
GlaxoSmithKline Pharmaceuticals FAQs
GlaxoSmithKline Pharmaceuticals share price is ₹2,320 As on 21 May, 2026 | 18:22
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹39314.1 Cr As on 21 May, 2026 | 18:22
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 37.9 As on 21 May, 2026 | 18:22
The PB ratio of GlaxoSmithKline Pharmaceuticals is 19.6 As on 21 May, 2026 | 18:22
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.